Compound Profile: Asthalin SA-
Asthalin SA-8 mg Cipla is a pharmaceutical-grade salbutamol formulation developed for in-vitro laboratory research. Salbutamol is a beta-2 adrenergic receptor agonist that has been extensively studied since its development in the 1960s. This bronchodilator compound demonstrates selective binding affinity for beta-2 adrenergic receptors, making it a valuable research tool for investigating respiratory physiology and adrenergic signalling pathways. The sustained-release (SA) formulation allows researchers to examine extended pharmacokinetic profiles in controlled laboratory environments. At Stroid UK Shop, this research-grade compound undergoes rigorous quality verification to ensure consistent results across experimental protocols.
Laboratory Research Applications
Researchers investigate salbutamol’s mechanism of action through various in-vitro studies examining beta-2 receptor binding kinetics and downstream cellular signalling cascades. The compound’s bronchodilator properties are studied in tissue culture models to understand smooth muscle relaxation mechanisms. Scientists analyse its effects on cyclic adenosine monophosphate (cAMP) levels and protein kinase A activation in respiratory cell lines. Research applications extend to pharmacokinetic studies, where the sustained-release properties are examined under controlled conditions. Comparative studies with other compounds in our salbutamol research collection provide valuable insights into receptor selectivity and therapeutic windows. Additional research focuses on metabolic pathways and cellular uptake mechanisms in pulmonary tissue models.
Compound Specifications
| Parameter | Value |
|---|---|
| Active Compound | Salbutamol |
| Formulation | Sustained Release 8mg |
| Manufacturer | Cipla Limited |
| CAS Number | 18559-94-9 |
| Molecular Formula | C₁₃H₂₁NO₃ |
| Molecular Weight | 239.31 g/mol |
| Storage Requirements | Room temperature, dry environment |
| Purity | Pharmaceutical grade |
This sustained-release formulation enables researchers to study extended pharmacological profiles compared to immediate-release preparations. The pharmaceutical-grade quality ensures reproducible experimental results across different research protocols. Storage recommendations maintain compound stability throughout the research period, while proper handling procedures preserve the integrity of the sustained-release matrix. Researchers examining alternative compounds may also investigate options from our SARMs research section or explore peptide research compounds for comparative studies.
Research Compliance Statement
Asthalin SA-8 mg Cipla is supplied exclusively for in-vitro laboratory research purposes and is not intended for human consumption, therapeutic use, or any application outside controlled research environments. Researchers must ensure compliance with all applicable regulations and institutional guidelines when conducting studies with this compound. Proper laboratory safety protocols, waste disposal procedures, and documentation requirements must be followed throughout the research process. This product is restricted to qualified research institutions and licensed laboratories with appropriate facilities and expertise in pharmaceutical research methodologies.
